Evidence map›Paper›PMID 26927042›Full record

ArticleMolecules (Basel, Switzerland)2016

Solanum nigrum Protects against Hepatic Fibrosis via Suppression of Hyperglycemia in High-Fat/Ethanol Diet-Induced Rats.

Cheng-Jeng Tai, Chen-Yen Choong, Yeu-Ching Shi, Yu-Chun Lin, Chia-Woei Wang, Bao-Hong Lee, Chen-Jei Tai

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Livogrit, a herbal formulation ofToxicology reports · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cheng-Jeng TaiDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medicine University Hospital, Taipei 11031, Taiwan. cjtai@tmu.edu.tw.
Chen-Yen ChoongDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. chenyen_318@hotmail.com.
Yeu-Ching ShiTaiwan Indigena Botanica Co., Ltd., Taipei 11458, Taiwan. jasmineycs@yahoo.com.tw.
Yu-Chun LinGraduate Institute of Medical Sciences, Taipei Medical University, Taipei 11031, Taiwan. doclin10@gmail.com.
Chia-Woei WangDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. cwwang@ms4.hinet.net.
Bao-Hong LeeDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medicine University Hospital, Taipei 11031, Taiwan. f96b47117@ntu.edu.tw.
Chen-Jei TaiDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. chenjtai@tmu.edu.tw.
Taipei Medical University Hospital · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced glycation end products (AGEs) signal through the receptor for AGE (RAGE), which can lead to hepatic fibrosis in hyperglycemia and hyperlipidemia. We investigated the inhibitory effect of aqueous extracts from Solanum nigrum (AESN) on AGEs-induced RAGE signaling and activation of hepatic stellate cells (HSCs) and hyperglycemia induced by high-fat diet with ethanol.

methodsAn animal model was used to evaluate the anti-hepatic fibrosis activity of AESN in rats fed a high-fat diet (HFD; 30%) with ethanol (10%). Male Wistar rats (4 weeks of age) were randomly divided into four groups (n = 6): (1) control (basal diet); (2) HFD (30%) + ethanol (10%) (HFD/ethanol); (3) HFD/ethanol + AESN (100 mg/kg, oral administration); and (4) HFD/ethanol + pioglitazone (10 mg/kg, oral administration) and treated with HFD for 6 months in the presence or absence of 10% ethanol in dietary water.

resultsWe found that AESN improved insulin resistance and hyperinsulinemia, and downregulated lipogenesis via regulation of the peroxisome proliferator-activated receptor α (PPARα), PPARγ co-activator (PGC-1α), carbohydrate response element-binding protein (ChREBP), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) mRNA levels in the liver of HFD/ethanol-treated rats. In turn, AESN may delay and inhibit the progression of hepatic fibrosis, including α-smooth muscle actin (α-SMA) inhibition and MMP-2 production.

conclusionsThese results suggest that AESN may be further explored as a novel anti-fibrotic strategy for the prevention of liver disease.

Indexed as

AnimalsDiet, High-FatEthanolGene Expression RegulationGlycation End Products, AdvancedHepatic Stellate CellsHyperglycemiaLipogenesisLiver CirrhosisMalePioglitazonePlant ExtractsRatsRats, WistarReceptor for Advanced Glycation End ProductsSolanum nigrumAger protein, ratEthanolGlycation End Products, AdvancedPioglitazonePlant ExtractsReceptor for Advanced Glycation End ProductsThiazolidinedionesadvanced glycation end products (AGEs)hepatic fibrosishyperglycemiahyperlipidemiaSolanum nigrum

Identifiers

PMID26927042
PMCPMC6274119
OpenAlexW2283254947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.